| EPB174 | Impact of intrinsic and extrinsic factors on the pharmacokinetics of long-acting lenacapavir for treatment of HIV | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB175 | Pharmacokinetic modeling and simulation of intramuscular and subcutaneous ibalizumab delivery | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB176 | Pharmacokinetics (PK) and tolerability of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) intramuscular (IM) injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB177 | Emtricitabine triphosphate in dried blood spots predicts current HIV viremia in people living with HIV and ongoing substance use disorders | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPB178 | Drug-drug interactions between antiretrovirals and remdesivir | E-poster | Drug interactions |
| EPB179 | Initiating long-acting cabotegravir and rilpivirine in a real-world setting ' clinical characteristics and switch reasons from people living with HIV (PLHIV) and health care provider perspective in the German CARLOS cohort | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB180 | Long-acting cabotegravir+rilpivirine in older adults: pooled Phase 3 Week 96 | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB181 | 'Give it a Shot': best practices from HCPs for administering long-acting cabotegravir+rilpivirine | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB182 | Long-acting cabotegravir+rilpivirine injection site reactions: pooled Week 96 results | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB183 | Week 96 weight and lipid changes from baseline among participants receiving cabotegravir and rilpivirine long-acting or comparator therapy in the ATLAS-2M and FLAIR studies | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |